NUVB -- SPAC offering February, 2021

SANA -- initial public offering February, 2021

BEAM -- initial public offering February, 2020

Developing curative cell-based immunotherapies for any cancer, with a focus on CAR-Ts and solid tumors

Expanding the therapeutic potential of small molecules to create transformative medicines

Developing defined complex microbial communities to provide a robust and lasting cure for high unmet need diseases

A cellular immunotherapy company creating a hybrid platform that integrates innate and adaptive programs to eliminate disease

Bringing the combined power of high-technology engineering and advanced biosynthesis to RNA therapeutics